Molecular determinants of response to high-dose daunorubicin induction chemotherapy. Benefit of high-dose versus standard-dose daunorubicin in patients with NPM1/DNMT3A mutations or with MLL translocations compared with those wild-type for all 3 AML disease alleles is shown (used with permission from Patel et al²¹ ).